BiomX announced the appointment of Susan Blum to its Board of Directors. Blum was also appointed to serve as a member and chair of the audit committee of the Board. Blum is the Chief Financial Officer of Melinta Therapeutics.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHGE:
- BiomX Announces the Appointment of Susan Blum to its Board of Directors
- BiomX Board Governance Structure and Bylaws Updated
- Biomx Inc. at a Crossroads: Shareholder Approval Required for Convertible Securities Amid Liquidity Concerns
- BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
- BiomX announces compliance with NYSE guidelines on audit opinion disclosure